These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 34725727

  • 41. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer.
    Pepe P, Pepe L, Cosentino S, Ippolito M, Pennisi M, Fraggetta F.
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [Abstract] [Full Text] [Related]

  • 42. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
    Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W.
    Theranostics; 2021 Jun; 11(17):8396-8411. PubMed ID: 34373749
    [Abstract] [Full Text] [Related]

  • 43. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
    Bodar YJL, Boevé LMS, van Leeuwen PJ, Baars PC, Nieuwenhuijzen JA, van Haarst EP, Oddens JR, Donswijk ML, van Riel LAMJG, Scheltema MJ, Meijer D, Hendrikse NH, Oprea-Lager DE, Vis AN.
    BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
    [Abstract] [Full Text] [Related]

  • 44. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L, Zhang G, Shi B, Liu Y, Zou T, Yan W, Xiao Y, Xue H, Feng F, Lei J, Jin Z, Sun H.
    Cancer Imaging; 2019 Dec 21; 19(1):90. PubMed ID: 31864408
    [Abstract] [Full Text] [Related]

  • 45. Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI.
    Lindenberg L, Mena E, Turkbey B, Shih JH, Reese SE, Harmon SA, Lim I, Lin F, Ton A, McKinney YL, Eclarinal P, Citrin DE, Dahut W, Madan R, Wood BJ, Krishnasamy V, Chang R, Levy E, Pinto P, Eary JF, Choyke PL.
    Radiology; 2020 Sep 21; 296(3):564-572. PubMed ID: 32633674
    [Abstract] [Full Text] [Related]

  • 46. Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [18F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients.
    Fu Y, Zhao M, Chen J, Wen Q, Chen B.
    Sci Rep; 2024 Jul 05; 14(1):15525. PubMed ID: 38969741
    [Abstract] [Full Text] [Related]

  • 47. Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W.
    Eur Radiol; 2023 Jan 05; 33(1):472-482. PubMed ID: 35864350
    [Abstract] [Full Text] [Related]

  • 48. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
    Privé BM, Israël B, Schilham MGM, Muselaers CHJ, Zámecnik P, Mulders PFA, Witjes JA, Sedelaar M, Mehra N, Verzijlbergen F, Janssen MJR, Gotthardt M, Barentsz JO, van Oort IM, Nagarajah J.
    Prostate Cancer Prostatic Dis; 2021 Jun 05; 24(2):423-430. PubMed ID: 32999466
    [Abstract] [Full Text] [Related]

  • 49. Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Liu Y, Dong Y, Liu J, Zhang X, Lin M, Xu B.
    Prostate; 2021 Dec 05; 81(16):1329-1336. PubMed ID: 34516670
    [Abstract] [Full Text] [Related]

  • 50. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L.
    BJU Int; 2023 May 05; 131(5):588-595. PubMed ID: 36371669
    [Abstract] [Full Text] [Related]

  • 51. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM, Kikano EG, Smith DA, Rao S, Podury R, Wang M, Durieux JC, Paspulati RM, Ponsky L, Ramaiya NH, Tirumani SH.
    AJR Am J Roentgenol; 2022 May 05; 218(5):859-866. PubMed ID: 34817189
    [Abstract] [Full Text] [Related]

  • 52. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, Schaeren E, Gu A, Langenegger N, Sulser T, Eberli D, Keller EX, Hermanns T, Poyet C.
    Prostate; 2022 Feb 05; 82(3):388-396. PubMed ID: 34914121
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Wang YF, Lo CY, Chen LY, Chang CW, Huang YT, Huang YY, Huang YH.
    Clin Nucl Med; 2023 Jul 01; 48(7):e321-e331. PubMed ID: 37145456
    [Abstract] [Full Text] [Related]

  • 59. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F, Stabile A, Mazzone E, Brembilla G, Sorce G, Pellegrino F, Scuderi S, Cannoletta D, Cirulli GO, Cucchiara V, Gandaglia G, De Cobelli F, Montorsi F, Briganti A.
    Urol Oncol; 2022 Mar 01; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [Abstract] [Full Text] [Related]

  • 60. The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
    Zhang X, Hong H, Liang D.
    Cancer Imaging; 2022 Oct 18; 22(1):60. PubMed ID: 36258247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.